Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Yuhan Replaces Merck To Market Samsung’s Biosimilars In Korea

Executive Summary

Local firm Yuhan is taking over from Merck as marketing partner in South Korea for Samsung Bioepis’ biosimilars amid speculation that weak sales of infliximab and etanercept may have triggered the realignment. Samsung Bioepis and Merck's broader partnership, however, remains intact.

You may also be interested in...



Samsung Bioepis Partners With Yuhan On Korean Adalimumab

Samsung Bioepis has added its Adalloce adalimumab version of Humira to its Korean biosimilars partnership with Yuhan Corporation, ahead of an imminent launch.

CHMP OKs First EU Biosimilar Herceptin, And Another Version Of Humira

Samsung Bioepis’s Ontruzant is set to be the first biosimilar version of Roche’s Herceptin on the EU market after getting the all-clear from the EMA’s CHMP on Sept. 15. The committee has also OKd another version of AbbVie’s Humira, this time from Boehringer Ingelheim.

Samsung Bioepis Builds Its Biosimilars Name In Europe

EU clearance of Samsung Bioepis' Imraldi, its adalimumab biosimilar, is the South Korean firm's third biosimilar anti-TNF alpha product to get approval in Europe.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB001732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel